Company Profile
Aclaris Therapeutics Stock Price, News & Analysis
- Ticker:
- ACRS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
6.09 USD (-4.25%)
Close
Last updated: August 6, 2026
647M USD
Market cap
Why the stock is moving
The latest monitored company update is “Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP).” The corresponding closing-price reaction is not yet available.
Company overview
Immuno-Inflammatory Drug Development
Aclaris Therapeutics develops biologic and oral therapies for immuno-inflammatory diseases. Its portfolio targets upstream cytokines and intracellular signaling pathways.
ATI-052
ATI-052 is a long-acting bispecific antibody against TSLP and IL-4 receptor alpha in proof-of-concept studies for asthma and atopic dermatitis.
Bosakitug
Bosakitug is an anti-TSLP monoclonal antibody in Phase 2 development for atopic dermatitis.
ATI-2138
ATI-2138 inhibits ITK and JAK3 and is being advanced through a Phase 2b basket strategy covering multiple forms of lichen planus.
ATI-9494
ATI-9494 is a next-generation oral ITK inhibitor approaching IND submission for broader immuno-inflammatory development.
Future catalysts
Topline Phase 1b data for ATI-052 in asthma and atopic dermatitis in the second half of 2026.
Initiation of the first part of a Phase 2b lichen-planus study of ATI-2138 in the second half of 2026.
IND submission for ATI-9494 in the second half of 2026.
Initiation of a Phase 2b asthma program for ATI-052 in the fourth quarter of 2026.
Topline Phase 2 data for bosakitug in the fourth quarter of 2026.
Recent news
- 01
- 02
Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Source: Aclaris Therapeutics
- 03
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Source: Aclaris Therapeutics
- 04
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
Source: Aclaris Therapeutics
- 05
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Source: Aclaris Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aclaris Therapeutics (ACRS)?
Aclaris Therapeutics (ACRS) most recently closed at 6.09 USD, a -4.25% move versus the previous session.
What is the market cap of Aclaris Therapeutics (ACRS)?
Aclaris Therapeutics currently has a market capitalization of 647M USD on BioPharmSignal.
What does Aclaris Therapeutics do?
Immuno-Inflammatory Drug Development Aclaris Therapeutics develops biologic and oral therapies for immuno-inflammatory diseases. Its portfolio targets upstream cytokines and intracellular signaling pathways. ATI-052 ATI-052 is a long-acting bispecific antibody against TSLP and IL-4 receptor alpha in proof-of-concept studies for asthma and atopic...
On which exchange is ACRS stock listed?
Aclaris Therapeutics (ACRS) is associated with NASDAQ, United States, Biopharma.
What is ATI-052?
Topline Phase 1b data for ATI-052 in asthma and atopic dermatitis in the second half of 2026.
Which conditions is Aclaris Therapeutics targeting with ATI-052?
Topline Phase 1b data for ATI-052 in asthma and atopic dermatitis in the second half of 2026.
How does Aclaris Therapeutics describe recent progress with ATI-052?
Topline Phase 1b data for ATI-052 in asthma and atopic dermatitis in the second half of 2026.
What is IL-4?
ATI-052 ATI-052 is a long-acting bispecific antibody against TSLP and IL-4 receptor alpha in proof-of-concept studies for asthma and atopic dermatitis.